Catalog No. A8193

ABT-737

Bcl-2抑制剂

规格	价格	货期
1mL(10 mM in DMSO)	￥772.00	现货
5mg	￥454.00	现货
10mg	￥818.00	现货
25mg	￥1700.00	现货
50mg	￥2727.00	现货
100mg	￥4363.00	现货
500mg	请咨询	现货

CAS号：852808-04-9纯度：97.61%

仅用于科研，不用于诊疗。未经明确授权不得转售。

021-55669583sales@apexbio.cnAPExBIO

特色产品

Annexin V-FITC/PI Apoptosis Kit

用于双染检测细胞凋亡和坏死

- 在10-20分钟内完成染色
- 适用于流式细胞仪和荧光显微镜检测
- 准确区分活细胞/凋亡细胞/坏死细胞

Phos binding reagent (Phosbind) acrylamide

分离和检测磷酸化/非磷酸化蛋白

- 新型的磷酸盐结合标签和功能分子
- 用于免疫印迹和质谱分析等后续操作
- 适用于30 KDa-130 KDa大小的蛋白

Cell Counting Kit-8 (CCK-8)

用于细胞增殖和细胞毒性试验

- 比MTT，MTS或WST-1更敏感
- 对细胞无毒性
- 步骤更简单，无需有机溶剂

Cy5 TSA Fluorescence System Kit

Cy5荧光标记的酪胺信号放大系统

- 检测ICC/IHC/ISH中的低丰度靶点
- 可将信号灵敏度提高100倍
- 同时保持稳定的特异性和分辨率

EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP)

用于观察mRNA运送，定位，翻译

- 具有Cap1结构的荧光素酶mRNA
- 提供更高的转录效率并抑制免疫激活
- 使用5-moUTP和Cy5-utp修饰

HotStart™ 2X Green qPCR Master Mix

用于荧光定量目标DNA或cDNA

- 通过热启动机制优化扩增特异性
- 优异的扩增效率、可重复性和稳定性
- 卓越的灵敏度和准确性，操作简单

HyperScribe™ T7 High Yield Cy5 RNA Labeling Kit Plus

高效的Cy5修饰RNA转录试剂盒

- 适合原位/Northernblot杂交实验
- 优化的缓冲液和T7 RNA聚合酶混合物
- 20 μL反应体系可获得更高的RNA产量

产品描述产品性质产品应用生物相关数据质量控制操作说明产品引用文献摩尔浓度计算器

产品描述

ABT-737（CAS号852808-04-9）是一种新型有效的BCL-2家族蛋白抑制剂，对BCL-X L、BCL-2和BCL-w有高亲和性，而对同源性较低的BCL-B、MCL-1及A1没有亲和性。BCL-2家族蛋白对许多肿瘤细胞中细胞的存活和过表达是至关重要的。ABT-737具有在体外和体内对抗淋巴瘤，小细胞肺癌和骨髓瘤的单药活性。最近的研究表明，ABT-737可以有效的杀死急性髓性白血病细胞、祖细胞和干细胞，而保留了完整的造血细胞。ABT-737可以扰乱BCL-2/BAX复合体，并以BAK依赖，而非BIM依赖的方式激活内在的凋亡途径。

参考文献：
Marina Konopleva, Rooha Contractor, Twee Tsao, Ismael Samudio, Peter P. Ruvolo, Shinichi Kitada, Xingming Deng, Dayong Zhai, Yue-Xi Shi, Thomas Sneed, Monique Verhaegen, Maria Soengas, Vivian R. Ruvolo, Teresa McQueen, Wendy D. Schober, Julie C. Watt, Tilahun Jiffar, Xiaoyang Ling, Frank C. Marini, David Harris, Martin Dietrich, Zeev Estrov, James McCubrey, W. Stratford May, John C. Reed, and Michael Andreeff. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006: 10; 375-388
Suzanne Trudel, A. Keith Stewart, Zhihua Li, Yanjun Shu, Sheng-Ben Liang, Young Trieu, Donna Reece, Josh Paterson, Dingyan Wang, and Xiao-Yan Wen. The Bcl-2 family protein inhibitor,ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin Cancer Res 2007; 13 (2) 621-629

产品性质

物理外观	A solid
CAS号	852808-04-9
分子式	C₄₂H₄₅ClN₆O₅S₂
分子量	813.43
化学名称	4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-N-[4-[[(2R)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide
溶解度	≥40.67 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O
SMILES	CN(C)CCC(CSC1=CC=CC=C1)NC2=C(C=C(C=C2)S(=O)(=O)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)CC5=CC=CC=C5C6=CC=C(C=C6)Cl)[N+](=O)[O-]
存储条件	-20°C
运输条件	蓝冰

产品应用 (实验数据来自文献，APExBIO并未验证，仅供参考)

IC50和靶点

生物活性描述	ABT-737是一种BH3模拟抑制剂，作用于Bcl-xL、Bcl-2和Bcl-w，非细胞试验中EC50分别为78.7 nM、30.3 nM和197.8 nM，但对Mcl-1、Bcl-B及Bfl-1没有抑制作用。
靶点	Bcl-xL	Bcl-2	Bcl-w
生物活性数据	78.7 nM (EC50)	30.3 nM (EC50)	197.8 nM (EC50)

生物相关数据

质量控制

请选择批次查看:

纯度 = 97.61%

COA (Certificate Of Analysis)HPLC (Retest)NMR (Nuclear Magnetic Resonance)MSDS (Material Safety Data Sheet)

操作说明

小分子化合物通用使用指南 Datasheet

APExBIO 顾客使用本产品发表的 35 篇科研文献

1. Jiyoon Park, Dawon Jeong, et al. "Sadoamides A and B: Bacterial Tripeptides Incorporating Nonproteinogenic Amino Acids as Proteasome Inhibitors." J Nat Prod. 2025 Dec 23. PMID: 41432229

2. Sukrut C. Kamerkar, Taewook Kang, et al. "The tumor suppressor LACTB remodels mitochondria to promote cytochrome c release and apoptosis." Sci Adv. 2025 Nov 14;11(46):eadx7809. PMID: 41223265

3. Nicholas W Harper, Gavin A Birdsall, et al. "RNA Pol II inhibition activates cell death independently from the loss of transcription." Cell. 2025 Aug 14:S0092-8674(25)00856-6. PMID: 40818455

4. Stefan Stoldt, Frederike Maass, et al. "Super-resolution microscopy of mitochondrial mRNAs." Nat Commun. 2025 Jul 10;16:6391. PMID: 40640125

5. Nicholas W. Harper, Gavin A. Birdsall et al. "Pol II degradation activates cell death independently from the loss of transcription." bioRxiv. 2025 Jan 14:2024.12.09.627542. PMID: 39713309

6. Louise E. King, Lukas Faber, et al. "Activator of apoptosis harakiri (HRK) localisation at mitochondria alters mitochondrial morphology independently of other BCL‐2 proteins." The FEBS Journal 26 August 2025

7. Hannah Esser, Alastair Morris Kilpatrick, et al. "Primary cilia as a targetable node between biliary injury, senescence and regeneration in liver transplantation." J Hepatol. 2024 Jun 13:S0168-8278(24)02302-X. PMID: 38879173

8. Jiayu Ye, John M. Baer, et al. "Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression." Cancer Discov. 2024 Apr 29. PMID: 38683161

9. Sarah V Schweighofer, Daniel C Jans, et al. "Endogenous BAX and BAK form mosaic rings of variable size and composition on apoptotic mitochondria." Cell Death Differ. 2024 Apr;31(4):469-478. PMID: 38503846

10. Esmee Vringer, Rosalie Heilig, et al. "Mitochondrial outer membrane integrity regulates a ubiquitin-dependent NF-κB inflammatory response." EMBO J. 2024 Mar;43(6):904-930. PMID: 38337057

11. Sookil Tae, Hye Yeon Lee, et al. "Senolytic and Senomorphic Effects of Lactobacillus plantarum DS0037 Derived Exosome-like Nanovesicles." Journal of the Society of Cosmetic Scientists of Korea Volume 50 Issue 4 / Pages.335-348 / 2024 / 1226-2587(pISSN) / 2288-9507(eISSN)

12. Esther A Guzmán, Tara A Peterson, et al. "The Marine Natural Compound Dragmacidin D Selectively Induces Apoptosis in Triple-Negative Breast Cancer Spheroids." Mar Drugs. 2023 Dec 15;21(12):642. PMID: 38132962

13. Qilian Ma, Jiaqi Xin, et al. "UBQLN2 and HSP70 participate in Parkin‐mediated mitophagy by facilitating outer mitochondrial membrane rupture." EMBO Rep. 2023 Sep 6;24(9):e55859. PMID: 37501540

14. Bianca A. Romo. "Estrogen Receptor (ER) Alpha Regulatory Mechanisms and Therapeutic Strategies in ER+ Breast Cancer." Dartmouth College. October 09, 2023

15. Anna L. Koessinger, Catherine Cloix, et al. "Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics." Cell Death Differ. 2022 Oct;29(10):2089-2104. PMID: 35473984

16. Schwartz, Hannah, et al. "In vitro Methods to Better Evaluate Drug Responses in Cancer." UMass Chan Medical School. September 8, 2022

17. Hector Flores-Romero, Lisa Hohorst, et al. "BCL‐2‐family protein tBID can act as a BAX‐like effector of apoptosis." EMBO J. 2021 Dec 21;e108690. PMID: 34931711

18. Florian J Bock, Egor Sedov, et al. "Apoptotic stress-induced FGF signalling promotes non-cell autonomous resistance to cell death." Nat Commun. 2021 Nov 12;12(1):6572. PMID: 34772930

19. Kirsteen J. Campbell, Susan M. Mason, et al. "Breast cancer dependence on MCL-1 is due to its canonical anti-apoptotic function." Cell Death Differ. 2021 Sep;28(9):2589-2600. PMID: 33785871

20. Alexander-Floyd J, Haroon S, et al. "Unexpected cell type-dependent effects of autophagy on polyglutamine aggregation revealed by natural genetic variation in C. elegans." BMC Biol. 2020;18(1):18. Published 2020 Feb 24. PMID: 32093691

21. Lee B, Min JA, et al. "A novel mechanism of irinotecan targeting MDM2 and Bcl-xL." Biochem Biophys Res Commun. 2019 Jun 25;514(2):518-523. PMID: 31056264

22. Thompson PJ, Shah A, et al. "Targeted Elimination of Senescent Beta Cells Prevents Type 1 Diabetes." Cell Metab. 2019 Feb 14. pii: S1550-4131(19)30021-X. PMID: 30799288

23. Sheridan J.S. Carrington. "Differential Glycosylation of the Inwardly Rectifying Potassium Channel Kir7.1 by G protein-coupled Receptors." Vanderbilt University. 2019

24. Yochum ZA, Cades J, et al. "Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer." Oncogene. 2018 Aug 31. PMID: 30171258

25. Jeong HJ, Ryu KJ, et al. "Anticancer agent ABT-737 possesses anti-atopic dermatitis activity via blockade of caspase-1 in atopic dermatitis in vitro and in vivo models." Immunopharmacol Immunotoxicol. 2018 Jun 29:1-8. PMID: 29957081

26. Kim HY, Jeong HJ, et al. "Anti-allergic and anti-inflammatory effects of the Bcl-2 inhibitor ABT-737 on experimental allergic rhinitis models." Eur J Pharmacol. 2018 May 30;833:34-43. PMID: 29856968

27. Cao Y, Chen M, et al. "The proton pump inhibitor pantoprazole disrupts protein degradation systems and sensitizes cancer cells to death under various stresses." Cell Death Dis. 2018 May 22;9(6):604. PMID: 29789637

28. Joel Riley, Giovanni Quarato, et al. "Activated BAX/BAK enable mitochondrial inner membrane permeabilisation and mtDNA release during cell death." bioRxiv. 2018 February 26

29. Giampazolias E, Zunino B, et al. "Mitochondrial permeabilization engages NF-κB-dependent anti-tumour activity under caspase deficiency." Nat Cell Biol. 2017 Sep;19(9):1116-1129. PMID: 28846096

30. Russo M, Milito A, et al. "CK2 and PI3K are direct molecular targets of quercetin in chronic lymphocytic leukaemia." Oncotarget. 2017 Jun 27;8(26):42571-42587. PMID: 28489572

31. Frevert, Marie Louise. "24 drugs as potential SKP2 Inhibitors: a novel approach to finding new antidepressants. Dissertation, LMU München: Medizinische Fakultät." d-nb.info. 2017

32. Xiang XY, Kang JS, et al. "SIRT3 participates in glucose metabolism interruption and apoptosis induced by BH3 mimetic S1 in ovarian cancer cells." Int J Oncol. 2016 Aug;49(2):773-84. PMID: 27277143

33. Kris Cameron Wood,Peter Saville Winter. "Compositions and Methods for Treating Cancer with JAK2 Activity." US Patent App. 15/027,216, 2016

34. Moriwaki, Kenta, et al. "The Mitochondrial Phosphatase PGAM5 Is Dispensable for Necroptosis but Promotes Inflammasome Activation in Macrophages." The Journal of Immunology (2015): 1501662. PMID: 26582950

35. Winter PS, et al. "RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis." Sci Signal. 2014 Dec 23. PMID: 25538080